
Nick Shaxson ■ Pfizer: tax dodger, price gouger

A new report from Americans for Tax Fairness concludes:
“In addition to dodging its fair share of taxes, Pfizer—maker of Celebrex, Lipitor, Lyrica, and Viagra, among many other health-care products—has also been aggressively raising prescription drug prices, thereby straining patients and our health care system and in some cases putting needed medications out of reach.
By dodging taxes while boosting prescription drug prices, Pfizer squeezes American families and communities from two sides at once. In the company’s biggest insult to America yet, Pfizer’s merger will allow it to go on enjoying all the benefits of being based here—everything from a publicly educated workforce to an excellent communications infrastructure to a reliable patent system—without adequately paying to support them.”
The two wealth-extracting techniques go together, very often. This is what modern capitalism is increasingly becoming.
Why doesn’t Pfizer’s leadership focus on what it was originally set up to do: wealth creation? And don’t get us started on shareholder value.
Related articles

Vulnerabilities to illicit financial flows: complementing national risk assessments

A tax justice lens on Palestine

New article explores why the fight for beneficial ownership transparency isn’t over
UN Submission: A Roadmap for Eradicating Poverty Beyond Growth
A human rights economy: what it is and why we need it

Strengthening Africa’s tax governance: reflections on the Lusaka country by country reporting workshop

Do it like a tax haven: deny 24,000 children an education to send 2 to school

Urgent call to action: UN Member States must step up with financial contributions to advance the UN Framework Convention on International Tax Cooperation

Incorporate Gender-Transformative Provisions into the UN Tax Convention
Asset beneficial ownership – Enforcing wealth tax & other positive spillover effects
4 March 2025